ARCUTIS BIOTHERAPEUTICS, INC. Amortization of Intangible Assets
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Amortization of Intangible Assets of $1.13 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2026-06-30 was $563.00K, a 0.00% change year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2026-03-31 was $562.00K, a 81.13% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2025-12-31 was $563.00K, a 79.87% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2025-09-30 was $562.00K, a 55.78% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. amortization of intangible assets for fiscal 2025 was $4.67M, a 138.23% increase from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. amortization of intangible assets for fiscal 2024 was $1.96M, a 161.20% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. amortization of intangible assets for fiscal 2023 was $750.00K, a 140.38% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. amortization of intangible assets for fiscal 2022 was $312.00K.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $563.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.13M 10-Q · filed 2026-08-05 | $1.69M derived: sum of 3 quarters · filed 2026-08-05 | $2.25M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $562.00K 10-Q · filed 2026-05-06 | $1.13M derived: sum of 2 quarters · filed 2026-05-06 | $1.69M derived: sum of 3 quarters · filed 2026-05-06 | $2.25M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $563.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.13M derived: sum of 2 quarters · filed 2026-02-25 | $1.69M derived: sum of 3 quarters · filed 2026-08-05 | $4.67M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $562.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $1.13M derived: sum of 2 quarters · filed 2026-08-05 | $4.10M 10-Q · filed 2025-10-28 | $4.42M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $563.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.54M 10-Q · filed 2026-08-05 | $3.85M derived: sum of 3 quarters · filed 2026-08-05 | $5.13M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $2.98M 10-Q · filed 2026-05-06 | $3.29M derived: sum of 2 quarters · filed 2026-05-06 | $4.56M derived: sum of 3 quarters · filed 2026-05-06 | $4.76M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $313.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.58M derived: sum of 2 quarters · filed 2026-02-25 | $1.78M derived: sum of 3 quarters · filed 2026-02-25 | $1.96M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $1.47M derived: sum of 2 quarters · filed 2025-10-28 | $1.65M 10-Q · filed 2025-10-28 | $1.85M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | $200.00K 10-Q · filed 2024-08-14 | $375.00K 10-Q · filed 2025-08-06 | $575.00K derived: sum of 3 quarters · filed 2026-02-25 | $188.57M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-03-31 | $188.00K 10-Q · filed 2025-05-06 | $375.00K derived: sum of 2 quarters · filed 2026-02-25 | $188.38M derived: sum of 3 quarters · filed 2026-02-25 | $188.57M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | $187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $188.19M derived: sum of 2 quarters · filed 2026-02-25 | $188.39M derived: sum of 3 quarters · filed 2026-02-25 | $750.00K 10-K · filed 2026-02-25 | |
| 2023-09-30 | $188.00M 10-Q · filed 2023-11-03 | $188.20M derived: sum of 2 quarters · filed 2024-08-14 | $563.00K 10-Q · filed 2024-11-06 | $188.57M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-06-30 | $200.00K 10-Q · filed 2024-08-14 | $188.00M 10-Q · filed 2023-08-08 | $376.00K 10-Q · filed 2024-08-14 | $575.00K derived: sum of 3 quarters · filed 2025-02-25 | $700.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $188.00K 10-Q · filed 2024-05-14 | $375.00K derived: sum of 2 quarters · filed 2025-02-25 | $500.00K derived: sum of 3 quarters · filed 2025-02-25 | $500.00K derived: sum of 4 quarters · filed 2025-02-25 | |
| 2022-12-31 | $187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $312.00K derived: sum of 2 quarters · filed 2025-02-25 | $312.00K derived: sum of 3 quarters · filed 2025-02-25 | $312.00K 10-K · filed 2025-02-25 | |
| 2022-09-30 | $125.00K 10-Q · filed 2023-11-03 | $125.00K derived: sum of 2 quarters · filed 2023-11-03 | $125.00K 10-Q · filed 2023-11-03 | $125.00K derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2024-02-27 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | ||||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |